When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
In the U.S., the chorus of opposition against the proposed merger continues to grow and now includes the CEOs of Roche and ...
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according ...
We recently compiled a list of the 10 Stocks Dominating a Billionaire Quant’s Investment Strategy. In this article, we are ...
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
A Johns Hopkins surgeon, Marty Makary also serves as a board member or adviser to several companies, including one that ...
As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...
Eli Lilly plans a $3 billion expansion of its Wisconsin facility, creating 750 skilled jobs and boosting production capacity ...
The European Commission granted unconditional approval to Novo Holdings’ $16.5 billion takeover of Catalent, a decision both ...